Breaking News Instant updates and real-time market news.

OPNT

Opiant Pharmaceuticals

$23.85

8.24 (52.79%)

, EBS

Emergent BioSolutions

$60.53

-1.03 (-1.67%)

10:36
08/29/18
08/29
10:36
08/29/18
10:36

Opiant jumps as analyst sees value after opioid overdose spray maker bought

Shares of Opiant Pharmaceuticals (OPNT) are on the rise after Emergent BioSolutions' (EBS) announced the acquisition of Adpat Pharma. Commenting on the deal, Cantor Fitzgerald analyst Brandon Folkes told investors he believes the acquisition underscores the potential for companies addressing the opioid overdose market, and that Opiant presents an attractive risk/reward, even if it captures only a portion of the growing market. EMERGENT ACQUIRES ADAPT PHARMA, NARCAN NASAL SPRAY: Emergent BioSolutions has announced that it has entered into an agreement to acquire Adapt Pharma and its flagship product Narcan Nasal Spray, the first and only needle-free formulation of naloxone approved by the Food and Drug Administration and Health Canada for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Total consideration for the transaction is up to $735M consisting of an upfront payment of $635M and up to $100M in cash for potential sales-based milestones through 2022. Upon the closing of the transaction, Emergent will acquire the Narcan Nasal Spray product and a development pipeline of new treatment and delivery options to address opioid overdose, and bring on approximately 50 employees, located in the U.S., Canada, and Ireland. Adapt Pharma is also developing new treatment and delivery options to address opioid overdoses. From a financial perspective, the company expects the incremental revenue contribution in 2019 from the acquisition to be between $200M-$220M. The company also anticipates that the transaction will be accretive to adjusted net income and EBITDA in 2019. VALUE IN OPIANT AFTER ADAPT DEAL: In a research note to investors, Cantor Fitzgerald's Folkes argued that Emergent BioSolutions' acquisition of Adapt Pharma underscores the value of the opioid overdose market. At a market cap of about $44M, the analyst pointed out he believes Opiant presents an attractive risk/reward, even if it captures only a portion of the growing market. Opiant is expected to generate about $30M-38M in cash from Narcan royalties and the milestone payment in 2019, to fund the development of its own opioid overdose nasal spray, OPNT003, and the other programs in the company's pipeline, he noted. Overall, Folkes said he expects investors to begin to appreciate the market potential of Opiant's pipeline, which should drive the stock higher. The analyst reiterated an Overweight rating and $32 price target on Opiant's shares. PRICE ACTION: In morning trading, Opiant's stock has jumped over 54% to $24 per share.

OPNT

Opiant Pharmaceuticals

$23.85

8.24 (52.79%)

EBS

Emergent BioSolutions

$60.53

-1.03 (-1.67%)

  • 29

    Aug

  • 05

    Sep

  • 05

    Sep

  • 01

    Oct

OPNT Opiant Pharmaceuticals
$23.85

8.24 (52.79%)

06/11/18
CANT
06/11/18
INITIATION
Target $32
CANT
Overweight
Opiant Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor initiated Opiant Pharmaceuticals with an Overweight and $32 price target.
06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
08/10/18
CANT
08/10/18
NO CHANGE
Target $32
CANT
Overweight
Cantor reiterates Overweight on Opiant ahead of pipeline readouts
Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Opiant Pharmaceuticals with a $32 price target following the company's Q2 results. The analyst expect investors to begin to appreciate the market potential of Opiant's pipeline, "which should drive the stock higher." The company is developing treatments focused on multiple addictions as well a new product for opioid overdose, Folkes tells investors in a research note titled "Pipeline Readouts in '18 and '19 Make Us Even More Positive on OPNT Stock."
08/29/18
CANT
08/29/18
NO CHANGE
Target $32
CANT
Overweight
Cantor sees value in Opiant after Emergent acquires Adapt Pharma
Cantor Fitzgerald analyst Brandon Folkes believes Emergent BioSolutions' (EBS) acquisition of Adapt Pharma underscores the potential for companies addressing the opioid overdose market. Opiant Pharmaceuticals (OPNT) is developing its own opioid overdose nasal spray, OPNT003, which could be of benefit in cases of synthetic opioid overdoses, such as with fentanyl, Folkes tells investors in a research note. He believes Opiant presents an attractive risk/reward at current share levels, "even if it captures only a portion of the growing market opioid overdose market." Folkes keeps an Overweight rating on the shares with a $32 price target.
EBS Emergent BioSolutions
$60.53

-1.03 (-1.67%)

08/10/18
WELS
08/10/18
NO CHANGE
Target $61
WELS
Market Perform
Emergent BioSolutions acquisition of PaxVax an 'excellent fit,' says Wells Fargo
After Emergent BioSolutions agreed to acquire PaxVax for $270M, Wells Fargo analyst David Maris said the transaction "sounds as though it is an excellent fit" and he is adding $70M in revenues for 2019 and assuming growth of 10% per year, though he thinks that could be conservative given the possible sales synergies. He also raised his price target on Emergent BioSolutions shares to $61 from $56, though he keeps a Market Perform rating on the shares.
08/29/18
CANT
08/29/18
NO CHANGE
Target $62
CANT
Overweight
Emergent acquisition should bridge guidance gap, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folkes believes Emergent BioSolutions' acquisition of Adapt Pharma and its opioid overdose product, Narcan nasal spray, should help "bridge the Street's gap" from the current 2020 consensus revenue estimate of $830M to the company's guidance of $1B. The analyst keeps an Overweight rating on Emergent with a $62 price target.
08/29/18
WELS
08/29/18
NO CHANGE
Target $65
WELS
Market Perform
Emergent deal for Adapt Pharma a 'bold' move with some risks, says Wells Fargo
Wells Fargo analyst David Maris said Emergent BioSolutions' agreement to acquire Adapt Pharma, the maker of Narcan nasal spray to treat opioid overdose, for about $735M is a "bold" move that some investors will like given the accretion and sales growth. However, some may see this as moving too far afield from its core business in biodefense and the deal may introduce overhang concerns about the duration of Narcan, added Maris. He raised his price target on Emergent shares to $65 from $61 and keeps a Market Perform rating on the stock.

TODAY'S FREE FLY STORIES

DIS

Disney

$137.30

2.2 (1.63%)

, CMCSA

Comcast

$42.95

1.08 (2.58%)

07:55
04/26/19
04/26
07:55
04/26/19
07:55
Periodicals
AI startup named Humu tries to block Hulu from brand confusion suit, WSJ says »

Over-the-top streaming…

DIS

Disney

$137.30

2.2 (1.63%)

CMCSA

Comcast

$42.95

1.08 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 08

    May

GPI

Group 1 Automotive

$76.26

1.59 (2.13%)

07:52
04/26/19
04/26
07:52
04/26/19
07:52
Downgrade
Group 1 Automotive rating change  »

Group 1 Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 13

    Nov

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

07:50
04/26/19
04/26
07:50
04/26/19
07:50
Recommendations
Amazon.com analyst commentary at Oppenheimer »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

  • 03

    Jun

INTC

Intel

$57.59

-1.13 (-1.92%)

07:49
04/26/19
04/26
07:49
04/26/19
07:49
Recommendations
Intel analyst commentary at Morgan Stanley »

Morgan Stanley still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

  • 03

    Jun

  • 25

    Jul

BC

Brunswick

$48.51

-6.01 (-11.02%)

07:48
04/26/19
04/26
07:48
04/26/19
07:48
Recommendations
Brunswick analyst commentary at SunTrust »

Brunswick price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

BMRN

BioMarin

$85.40

-0.06 (-0.07%)

07:48
04/26/19
04/26
07:48
04/26/19
07:48
Recommendations
BioMarin analyst commentary at Cantor Fitzgerald »

Cantor continues to see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

07:47
04/26/19
04/26
07:47
04/26/19
07:47
Recommendations
Amazon.com analyst commentary at Credit Suisse »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

  • 03

    Jun

DOW

Dow Inc.

$55.33

-0.67 (-1.20%)

07:47
04/26/19
04/26
07:47
04/26/19
07:47
Initiation
Dow Inc. initiated  »

Dow Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 29

    May

MMM

3M

$190.67

-28.57 (-13.03%)

07:46
04/26/19
04/26
07:46
04/26/19
07:46
Downgrade
3M rating change  »

3M downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

  • 18

    May

  • 29

    May

WING

Wingstop

$77.85

0.03 (0.04%)

07:46
04/26/19
04/26
07:46
04/26/19
07:46
Hot Stocks
Wingstop launches delivery in Dallas as part of national rollout with DoorDash »

Wingstop has officially…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

07:45
04/26/19
04/26
07:45
04/26/19
07:45
General news
Treasury Market Outlook: bond yields richened overnight »

Treasury Market Outlook:…

RGEN

Repligen

$57.24

1.04 (1.85%)

07:44
04/26/19
04/26
07:44
04/26/19
07:44
Hot Stocks
Repligen to acquire C Technologies for $240M in cash, stock »

Repligen announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 28

    May

  • 13

    Nov

ADS

Alliance Data

$153.85

-9.69 (-5.93%)

07:44
04/26/19
04/26
07:44
04/26/19
07:44
Recommendations
Alliance Data analyst commentary at BMO Capital »

Alliance Data price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 13

    Nov

CLF

Cleveland-Cliffs

$9.71

0.19 (2.00%)

07:44
04/26/19
04/26
07:44
04/26/19
07:44
Upgrade
Cleveland-Cliffs rating change  »

Cleveland-Cliffs upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOCA

Tocagen

$9.13

0.63 (7.41%)

07:44
04/26/19
04/26
07:44
04/26/19
07:44
Initiation
Tocagen initiated  »

Cantor starts Tocagen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TILE

Interface

$15.67

-1.44 (-8.42%)

07:41
04/26/19
04/26
07:41
04/26/19
07:41
Hot Stocks
Interface Chief Accounting Officer put on administrative leave amid SEC probe »

Interface received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    May

AMZN

Amazon.com

$1,902.53

1.81 (0.10%)

07:41
04/26/19
04/26
07:41
04/26/19
07:41
Recommendations
Amazon.com analyst commentary at KeyBanc »

Amazon's 1-day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 22

    May

  • 03

    Jun

INTC

Intel

$57.59

-1.13 (-1.92%)

07:41
04/26/19
04/26
07:41
04/26/19
07:41
Recommendations
Intel analyst commentary at Credit Suisse »

Intel structural thesis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 16

    May

  • 03

    Jun

  • 25

    Jul

AAL

American Airlines

$33.36

-0.64 (-1.88%)

07:40
04/26/19
04/26
07:40
04/26/19
07:40
Hot Stocks
American Airlines sees Q2 TRASM up 1%-3% y/y »

The company also expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 21

    May

  • 29

    May

  • 12

    Jun

AAL

American Airlines

$33.36

-0.64 (-1.88%)

07:40
04/26/19
04/26
07:40
04/26/19
07:40
Hot Stocks
American Airlines reports Q1 PRASM up 0.6% »

Passenger demand drove a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 21

    May

  • 29

    May

  • 12

    Jun

07:40
04/26/19
04/26
07:40
04/26/19
07:40
General news
Oil Action: WTI crude »

Oil Action: WTI crude has…

TMUS

T-Mobile

$72.68

-0.67 (-0.91%)

, S

Sprint

$5.61

-0.01 (-0.18%)

07:39
04/26/19
04/26
07:39
04/26/19
07:39
Recommendations
T-Mobile, Sprint analyst commentary  »

T-Mobile price target…

TMUS

T-Mobile

$72.68

-0.67 (-0.91%)

S

Sprint

$5.61

-0.01 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

07:38
04/26/19
04/26
07:38
04/26/19
07:38
Conference/Events
The National Press Club to host a luncheon meeting »

Panera Bread Founder…

PRO

Pros Holdings

$45.06

-0.25 (-0.55%)

07:37
04/26/19
04/26
07:37
04/26/19
07:37
Recommendations
Pros Holdings analyst commentary  »

ProsHoldings price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

PFPT

Proofpoint

$131.35

3.56 (2.79%)

07:36
04/26/19
04/26
07:36
04/26/19
07:36
Recommendations
Proofpoint analyst commentary at KeyBanc »

Proofpoint price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.